These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12645392)

  • 1. [Changes in tumor markers CEA, Ca 19-9 and Ca 125 in monitoring of response to chemotherapy in elderly patients with advanced gastric cancer].
    Caponetti R; Caponetti T; Vici P
    Clin Ter; 2002; 153(6):373-5. PubMed ID: 12645392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer.
    Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(44):388-92. PubMed ID: 11995458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The changes in tumor markers such as serum CEA, CA 19-9, TPA and CA 125 in the chemotherapy of patients with advanced gastric cancer].
    Imamura Y; Yasutake K; Yoshimura Y; Oya M; Matsushita K; Tokisue M; Ohno S; Masuda T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1501-7. PubMed ID: 2143888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.
    Okusaka T; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
    Hepatogastroenterology; 1998; 45(21):867-72. PubMed ID: 9684148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
    Yamao T; Kai S; Kazami A; Koizumi K; Handa T; Takemoto N; Maruyama M
    Jpn J Clin Oncol; 1999 Nov; 29(11):550-5. PubMed ID: 10678558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer.
    Kim HJ; Lee KW; Kim YJ; Oh DY; Kim JH; Im SA; Lee JS
    Acta Oncol; 2009; 48(3):385-90. PubMed ID: 18855156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer.
    Dilege E; Mihmanli M; Demir U; Ozer K; Bostanci O; Kaya C; Aksakal O; Sakiz D
    Hepatogastroenterology; 2010; 57(99-100):674-7. PubMed ID: 20698248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in tumor marker levels as a predictor of chemotherapeutic effect in patients with gastric carcinoma.
    Nakata B; Chung KH; Muguruma K; Yamashita Y; Inoue T; Matsuoka T; Onoda N; Kato Y; Sakurai M; Sowa M
    Cancer; 1998 Jul; 83(1):19-24. PubMed ID: 9655288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical courses of serum tumor markers--4 case reports.
    Klapdor R; Bahlo M; Babinski A
    Anticancer Res; 2003; 23(2A):845-50. PubMed ID: 12820311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoembryonic antigen level is related to tumor invasion into the serosa of the stomach: study on 166 cases and suggestion for new therapy.
    Zhang YH; Li Y; Chen C; Peng CW
    Hepatogastroenterology; 2009; 56(96):1750-4. PubMed ID: 20214231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Stage IV gastric cancer patient who underwent palliative gastrectomy showing complete response to induction therapy with methotrexate plus 5-fluorouracil and secondary treatment with oral TS-1].
    Hiramatsu K; Mizukami Y; Momiyama M; Suzuki M; Niimi K; Nagashima T
    Gan To Kagaku Ryoho; 2005 Aug; 32(8):1163-6. PubMed ID: 16121921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of tumor markers as predictors of prognosis in gastric cancer.
    Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
    Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer.
    Ishii H; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
    Hepatogastroenterology; 1997; 44(13):279-83. PubMed ID: 9058159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer].
    Uehara M; Manaka D; Baba S; Oji Y; Hirata K; Shimizu M; Noguchi M
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1413-7. PubMed ID: 17876139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
    Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
    Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer.
    Imada T; Rino Y; Takahashi M; Hatori S; Shiozawa M; Amano T; Kondo J
    Hepatogastroenterology; 1999; 46(27):2086-90. PubMed ID: 10430402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.
    Park YA; Sohn SK; Seong J; Baik SH; Lee KY; Kim NK; Cho CW
    J Surg Oncol; 2006 Feb; 93(2):145-50. PubMed ID: 16425302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma.
    Tanaka K; Miki C; Wakuda R; Kobayashi M; Tonouchi H; Kusunoki M
    Scand J Gastroenterol; 2004 Aug; 39(8):754-60. PubMed ID: 15513361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.